Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M528Revenue $M1.1Net Margin (%)-3,300.8Altman Z-Score-0.8
Enterprise Value $M390EPS $-0.2Operating Margin %-3,361.7Piotroski F-Score4
P/E(ttm)--Beneish M-Score-5.2Pre-tax Margin (%)-3,300.8Higher ROA y-yY
Price/Book4.510-y EBITDA Growth Rate %-11.6Quick Ratio3.4Cash flow > EarningsY
Price/Sales4675-y EBITDA Growth Rate %-25.8Current Ratio3.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-23.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-28.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M158ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GERN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
GERNFirst Eagle Investment 2015-06-30 Reduce-0.01%$3.62 - $4.33
$ 3.34-16%Reduce 77.40%164,700
GERNFirst Eagle Investment 2015-03-31 Reduce$2.81 - $4.34
$ 3.34-1%Reduce 35.43%728,866
GERNFirst Eagle Investment 2014-12-31 Reduce-0.01%$1.85 - $3.84
$ 3.3420%Reduce 48.64%1,128,866
GERNFirst Eagle Investment 2014-09-30 Reduce-0.01%$2.12 - $3.014
$ 3.3436%Reduce 38.05%2,198,124
GERNFirst Eagle Investment 2014-03-31 Add0.01%$1.6 - $5.4
$ 3.34-17%Add 46.43%3,054,252
GERNFirst Eagle Investment 2013-03-31 Add$1.01 - $1.64
$ 3.34142%Add 36.91%2,410,934
GERNGeorge Soros 2011-03-31 Sold Out $4.44 - $5.07
$ 3.34-29%Sold Out0
GERNFirst Eagle Investment 2010-12-31 Add0.03%$4.46 - $6.02
$ 3.34-36%Add 74.80%2,570,500
GERNGeorge Soros 2010-12-31 Buy $4.46 - $6.02
$ 3.34-36%New holding26,500
GERNFirst Eagle Investment 2010-06-30 Add0.02%$4.67 - $5.81
$ 3.34-35%Add 77.56%1,420,500
GERNFirst Eagle Investment 2010-03-31 Add0.03%$4.97 - $6.21
$ 3.34-40%Add 204.80%800,000
GERNFirst Eagle Investment 2009-12-31 Add0.02%$4.91 - $6.69
$ 3.34-40%Add 556.18%262,471
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GERN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

GERN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BEHRS MELISSA KELLYEVP BD and Port&Alliance Mgmt 2015-05-29Sell2,380$3.84-10.16view
Bloom Olivia KyusukEVP, CFO 2015-05-29Sell2,380$3.84-10.16view
Hofstaetter ThomasDirector 2015-03-18Sell70,000$4.1-15.85view
Bloom Olivia KyusukEVP, CFO 2014-05-29Sell3,379$2.164.29view
BEHRS MELISSA KELLYEVP Portfolio & Alliance Mgmt 2014-05-29Sell4,826$2.164.29view
BRADBURY DANIELDirector 2014-05-09Buy142,776$1.7597.14view
BEHRS MELISSA KELLYEVP Portfolio & Alliance Mgmt 2014-04-01Sell12,310$2.1361.97view
Bloom Olivia KyusukEVP, CFO 2014-04-01Sell7,435$2.1361.97view
SCARLETT JOHN APresident and CEO 2013-04-01Buy50,000$1.03234.95view
BEHRS MELISSA KELLYSVP Alliance and Prog Mgmt 2013-01-17Sell28,292$1.65109.09view

Quarterly/Annual Reports about GERN:

    News about GERN:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
    Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
    Geron: Buyer Beware Oct 13 2010 
    Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 
    Geron Corp. (GERN) EVP and CFO David Greenwood sells 14,746 Shares Jun 03 2010 
    Geron Corporation Reports 2009 Second Quarter Financial Results and Events Jul 30 2009 
    Geron Corp (GERN): Stock of the Day Mar 10 2009 
    Banking 60% on the Day the World Changed: FDA Approves Geron to Test Embryonic Stem Cells on Humans Jan 24 2009 
    The Next Boom Emerges Nov 23 2008 

    More From Other Websites
    Geron Corporation (GERN) And Lannett Company, Inc. (LCI): Two Pharmaceutical Stocks Making Big Gains... Sep 03 2015
    Geron shares jump after two positive drug studies Sep 02 2015
    Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of... Sep 02 2015
    Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of... Sep 02 2015
    5:02 pm Geron announces publication of two papers in The New England Journal of Medicine that... Sep 02 2015
    Asterias's stem cell therapy shows promise in study Aug 31 2015
    GERON CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Aug 28 2015
    GERON CORP Financials Aug 14 2015
    10-Q for Geron Corp. Aug 07 2015
    Geron Q2 Loss Narrower-than-Expected, Imetelstat in Focus - Analyst Blog Aug 06 2015
    Geron Corporation Reports Second Quarter 2015 Financial Results Aug 05 2015
    GERON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 05 2015
    GERON CORP Files SEC form 10-Q, Quarterly Report Aug 05 2015
    Geron Corporation Reports Second Quarter 2015 Financial Results Aug 05 2015
    Can the Rally in Geron (GERN) Shares Continue? - Tale of the Tape Jun 24 2015
    GERON CORP Files SEC form 8-K, Regulation FD Disclosure Jun 15 2015
    Why Geron (GERN) Might Be a Diamond in the Rough - Tale of the Tape May 26 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)